Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Orphan designations Remove Orphan designations filter Summaries of opinion (18) Apply Summaries of opinion filter Referrals (17) Apply Referrals filter Direct healthcare professional communication (10) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (358) Apply Authorised filter Refused (14) Apply Refused filter Withdrawn (29) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (36) Apply Initial authorisation filter Post-authorisation (13) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (17) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (139) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (30) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (19) Apply Yes filter

Compliance procedure number

Orphan disease / condition

Orphan decision number

Orphan designation status

Positive (207) Apply Positive filter Withdrawn (1) Apply Withdrawn filter

Medicine type

Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter Accelerated assessment (98) Apply Accelerated assessment filter Biosimilar (71) Apply Biosimilar filter Conditional approval (76) Apply Conditional approval filter Exceptional circumstances (62) Apply Exceptional circumstances filter Generic (273) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

846 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Orphan designations Remove Orphan designations filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter

Categories Human Remove Human filter

Medicine type Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter

Sort by

List item

Human medicine European public assessment report (EPAR): Mvabea (updated)

Recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP, Hemorrhagic Fever, Ebola
Date of authorisation: 01/07/2020, , , Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Lamzede (updated)

velmanase alfa, alpha-Mannosidosis
Date of authorisation: 23/03/2018, , , , Revision: 3, Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Alofisel (updated)

darvadstrocel, Rectal Fistula
Date of authorisation: 23/03/2018, , , Revision: 5, Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Orkambi (updated)

Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015, , Revision: 23, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Skyrizi (updated)

Risankizumab, Psoriasis
Date of authorisation: 26/04/2019, , Revision: 4, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 17, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Veklury (updated)

remdesivir, Coronavirus Infections
Date of authorisation: 03/07/2020, , , Revision: 1, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Imraldi (updated)

adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Arthritis, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 24/08/2017, , , Revision: 13, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Darzalex (updated)

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , , Revision: 14, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Mysimba (updated)

bupropion hydrochloride, naltrexone hydrochloride, Obesity, Overweight
Date of authorisation: 26/03/2015, , Revision: 17, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Ondexxya (updated)

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 6, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Cablivi (updated)

Caplacizumab, Purpura, Thrombotic Thrombocytopenic
Date of authorisation: 30/08/2018, , , Revision: 4, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Myalepta (updated)

Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018, , , , Revision: 4, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Zavicefta (updated)

avibactam sodium, ceftazidime pentahydrate, Pneumonia, Bacterial, Soft Tissue Infections, Pneumonia, Urinary Tract Infections, Gram-Negative Bacterial Infections
Date of authorisation: 23/06/2016, , Revision: 10, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Polivy (updated)

polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020, , , , Revision: 1, Authorised, Last updated: 19/11/2020
List item

Human medicine European public assessment report (EPAR): Gilenya (updated)

fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011, , , Revision: 26, Authorised, Last updated: 19/11/2020
List item

Human medicine European public assessment report (EPAR): Flucelvax Tetra (updated)

Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/Hawaii/70/2019 (H1N1)pdm09-like strain (A/Nebraska/14/2019, wild type); A/Hong Kong/45/2019 (H3N2)-like strain (A/Delaware/39/2019, wild type); B/Washington/02/2019-like strain (B/Darwin/7/2019, wild type); B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type), Influenza, Human
Date of authorisation: 12/12/2018, , Revision: 6, Authorised, Last updated: 18/11/2020
List item

Human medicine European public assessment report (EPAR): Keytruda (updated)

Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015, , Revision: 29, Authorised, Last updated: 17/11/2020
List item

Human medicine European public assessment report (EPAR): Procysbi (updated)

mercaptamine bitartrate, Cystinosis
Date of authorisation: 05/09/2013, , Revision: 13, Authorised, Last updated: 17/11/2020
List item

Human medicine European public assessment report (EPAR): Glyxambi (updated)

empagliflozin, linagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 11/11/2016, , Revision: 11, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Zirabev (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019, , , Revision: 5, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Equidacent (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Date of authorisation: 24/09/2020, , Revision: 1, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Besponsa (updated)

inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 28/06/2017, , , Revision: 7, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Talzenna (updated)

talazoparib, Breast Neoplasms
Date of authorisation: 20/06/2019, , Revision: 3, Authorised, Last updated: 13/11/2020
List item

Human medicine European public assessment report (EPAR): Nubeqa (updated)

darolutamide, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 27/03/2020, , Revision: 2, Authorised, Last updated: 13/11/2020